ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AZ to take $100m hit from ending trial of CV drug Epanova pharmaceutical-technology
January 15, 2020AstraZeneca (AZ) has announced the termination of its Phase III STRENGTH trial of Epanova (omega-3 carboxylic acids) following a recommendation by an Independent Data Monitory Committee that the drug was unlikely to demonstrate cardiovascular (CV) benefit
Pharma Sources Insight July 2025
